Lbpharma
2 known investors
LB Pharma develops novel therapies for neuropsychiatric disorders, with a lead product candidate called LB-102, an oral small molecule benzamide antipsychotic targeting schizophrenia, bipolar depression, and other neuropsychiatric diseases.
BiotechDigital Health